Compare WHR & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WHR | PHVS |
|---|---|---|
| Founded | 1911 | 2015 |
| Country | United States | Switzerland |
| Employees | 41000 | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.4B |
| IPO Year | 1994 | 2020 |
| Metric | WHR | PHVS |
|---|---|---|
| Price | $31.85 | $32.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $74.33 | $41.82 |
| AVG Volume (30 Days) | ★ 2.6M | 1.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | ★ 196.42 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $21,253,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.58 | N/A |
| 52 Week Low | $31.52 | $20.65 |
| 52 Week High | $94.82 | $43.25 |
| Indicator | WHR | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 32.89 | 33.49 |
| Support Level | N/A | $25.17 |
| Resistance Level | $45.07 | $36.80 |
| Average True Range (ATR) | 1.36 | 2.22 |
| MACD | -0.18 | -0.66 |
| Stochastic Oscillator | 5.80 | 3.57 |
Whirlpool Corp is a manufacturer and marketer of kitchen and laundry appliances, with its presence in different markets around the world. It offers products like refrigerators, washing machines, cooktops, ovens, freezers, and others, which are marketed through various brands such as KitchenAid, Maytag, Amana, Brastemp, Consul, Whirlpool, Jennair, etc. The company's operating and reportable segments are: Major Domestic Appliances (MDA) North America (its key revenue-generating segment), MDA Europe, MDA Latin America, and Small Domestic Appliances (SDA) Global.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.